Skip to main content

Vida Animal Health

Division

Therapeutics

Oral solid dosage form

  • Chagas Disease
  • Leishmania-cutaneous & visceral
  • 2nd generation products—new formulations and indications
  • Early-Stage assets

Diagnostics

Point of Care, Serologic Lateral Flow Assays

  • Chagas Disease Test
  • Leishmania Test
  • 2nd generation products—new formulations and indications
  • Early-Stage assets

Laboratory Services

  • Bioanalytic
  • PCR Testing

Vida Human Health

Division

Therapeutics

Oral solid dosage form

  • Chagas Disease
  • Leishmania-cutaneous & visceral
  • 2nd generation products—new formulations and indications
  • Early-Stage assets

Diagnostics

Point of Care, Serologic Lateral Flow Assays

  • Chagas Disease Test
  • Leishmania Test
  • 2nd generation products—new formulations and indications
  • Early-Stage assets

Laboratory Services

  • Bioanalytic
  • PCR Testing

Our Team

Roy Madigan, D.V.M.

Diretor Executivo e Fundador

Roy T. Madigan, D.V.M., é o principal cientista no estudo canino Chagas tratamento, Lackland Air Force base, San Antonio, TX-investigação sobre o tratamento da doença de Chagas canina em une Estados exército militar cães de trabalho. Madigan é também o diretor do hospital animal de Smithson Valley em Spring Branch, TX (diretor médico e coordenador de medicina animal de pequeno porte). É o fundador da Vida Pharmacal, uma empresa de manufatura farmacêutica sem fins lucrativos e veterinária. O foco da empresa é o desenvolvimento de novas terapêuticas para abordar doenças parasitas negligenciadas em humanos e animais. O trabalho de Madigan inclui arquivar a primeira patente veterinária de drogas para o anti-T. cruzada atividade em cães e realização de pesquisas pioneiras no estudo dos efeitos curativos da combinação de drogas em células cardíacas humanas infectadas com a doença de Chagas. Ele é um membro da força-tarefa do Texas Chagas, centros de controle de doenças e da Universidade do Texas Health Science Center, San Antonio, TX, como o chumbo veterinário para a doença de Chagas canina no Texas. A força-tarefa aumenta a conscientização pública da doença de Chagas, trabalhando com provedores de saúde, entomologistas, marketing e o público. Ele está trabalhando com o FDA para aprovação de regimes de tratamento para canino Chagas, e com os laboratórios comerciais para desenvolver técnicas serológico para diagnosticar a infecção T. cruzi em cães. Ele reside no Texas Hill Country com sua esposa, dois filhos, cinco cães, gato e furão.

John Librie

Chief Executive Officer

John joined Vida Pharmacal as CEO in 2022, bringing over 35 years of executive-level experience with start-up biopharmaceutical companies. Prior to joining Vida, John founded Velcision LLC, a highly successful commercialization company providing startup companies with executive leadership and expertise in commercial, regulatory, clinical, manufacturing, and operations. He has a successful track record of building companies, commercial launches, significant revenue generation, and profitability. John’s additional experience includes fund raising and in-licensing and out-licensing products. John previously served as CEO at Cellular Preservation Technologies, ONY Biotech, and Shore Therapeutics. He was senior vice president, Sales & Marketing, at Acorda Therapeutics, where he helped drive the company’s initial public offering (IPO). As a regional director, he played a key role in the commercialization of Genentech in the early days of the biotechnology industry.

Gerard Cignarella

Chief Financial Officer & Chief Business Officer

Gerard currently serves as the CFO and CBO at Vida Pharmacal Inc., where he leads corporate development, finance, M&A, and global business development activities. Gerard's executive experience spans more than 30 years of success in leading and executing corporate development, finance, merger-and-acquisition, and business development transactions. Throughout his career, he has been responsible for conceiving, developing, and executing strategies and initiatives for driving revenue, growth, competitive marketing position, profits, and shareholder value. Prior to joining Vida, Gerard held progressive senior executive level positions at Pfizer Inc., Acorda Therapeutics, Retrophin, and Kora Healthcare LTD—as well as led startups and consulting companies.